Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT1 | P04628 | 8/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | CCR2 | P41597 | 4/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 10/20 | 0.38 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.37 |
| ▸ | CLK2 | P49760 | 2/20 | 0.37 |
| ▸ | CLK3 | P49761 | 2/20 | 0.37 |
| ▸ | GLS | O94925 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3792349 | 0.93 | CCR2 (0.45) | GSK3BCCR2MCHR2KCNH2 | |
| SCHEMBL3781517 | 0.87 | DRD4 (0.46) | CCR2 | |
| SCHEMBL4128765 | 0.85 | CCR2 (0.38) | WNT1CCR2DYRK1AMCHR2GLS | |
| SCHEMBL3784437 | 0.82 | CCR2 (0.35) | CCR2MCHR2GLSKCNH2 | |
| SCHEMBL3787852 | 0.81 | CCR2 (0.37) | CCR2GLSKCNH2 | |
| SCHEMBL3028961 | 0.81 | CCR2 (0.37) | CCR2GLSKCNH2 | |
| SCHEMBL3776521 | 0.80 | PARP1 (0.44) | MCHR2KCNH2 | |
| SCHEMBL3787792 | 0.79 | DRD4 (0.47) | CCR2 | |
| SCHEMBL3782902 | 0.79 | KCNH2 (0.39) | CCR2MCHR2GLSKCNH2 | |
| SCHEMBL3785872 | 0.79 | CCR2 (0.38) | CCR2GLSKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-30 | — | — | US | claimed |
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-30 | — | — | US | disclosed |
| WO-2009076404-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF THE CHEMOKINE CCR2 RECEPTOR | EPIX DELAWARE, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CCR2, CCR1, CCR5 | WNT1 4225/4885GSK3B 3285/4885CCR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.